3rd Quarter - Amendment

MERCK & CO, INC. for MERCK & CO INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,160,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 20, 2014 $1,160,000 Replaced
3rd Quarter - Amendment (this page) Jan 26, 2015 $1,160,000 Replaced
3rd Quarter - Amendment Oct 7, 2015 $1,160,000 Replaced
3rd Quarter - Amendment Sep 6, 2016 $1,160,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Animals ANI

Education on beta-agonists (no specific bill), education on antibiotics and veterinary biologics (no specific bill)

LobbyistCovered position, as disclosed
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
JEROME MURRAY —
KATIE OPPENHEIM —
ERIN POLAK —
ANGELA M STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —
ANGELA M STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1128 (113th)

Copyright/Patent/Trademark CPT

Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)

LobbyistCovered position, as disclosed
ERIN DARLING —
ANGELA M STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Additives in beef cattle (no specific bill)

LobbyistCovered position, as disclosed
ELI JOSEPH —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
PATRICK LIEDTKA —
JEROME MURRAY —
KATIE OPPENHEIM —
ERIN POLAK —
ANGELA M STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1074 (113th), S. 539 (113th), H.R. 3322 (113th), H.R. 2925 (113th), H.R. 3116 (113th), H.R. 4187 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.